Sign in

What researchers published on Mesothelioma

6,202 papers, newest first.

Showing 20 of 187

  • Trial resultPreclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nature communications
  • Trial resultCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.Clinical lung cancer
  • Randomised trialGemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.BMC cancer
  • Trial resultPhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.The Journal of thoracic and cardiovascular surgery
  • Randomised trialFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Trial resultPembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial.Clinical lung cancer
  • Randomised trialEvaluation of an educational program for nurses on the care coordination of pleural mesothelioma patients: A pilot randomized controlled trial.Japan journal of nursing science : JJNS
  • Trial resultPhase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.Molecular therapy : the journal of the American Society of Gene Therapy
  • Randomised trialNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).Lung cancer (Amsterdam, Netherlands)
  • Trial resultPembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.The Lancet. Oncology
  • Trial resultFirst-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.ESMO open
  • Trial resultYAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.Nature medicine
  • Trial resultPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.Nature medicine
  • Randomised trialA randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma.Future oncology (London, England)
  • Trial resultKEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer science
  • Trial resultEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.Lung cancer (Amsterdam, Netherlands)
  • Trial resultAd-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research
  • Randomised trialEvaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer.Clinical and translational science
  • Trial resultWT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.Journal of hematology & oncology
  • Randomised trialA randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.Annals of oncology : official journal of the European Society for Medical Oncology